Zoetis Inc. Files 8-K on Officer Changes and Shareholder Votes

Ticker: ZTS · Form: 8-K · Filed: 2025-05-22T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, officer-changes, shareholder-vote

Related Tickers: ZTS

TL;DR

Zoetis filed an 8-K detailing exec changes, director elections, and shareholder votes.

AI Summary

Zoetis Inc. filed an 8-K on May 21, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 10 Sylvan Way, Parsippany, New Jersey.

Why It Matters

This filing provides crucial updates on Zoetis's corporate governance and executive appointments, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: low — This is a routine corporate filing detailing standard governance and reporting events.

Key Players & Entities

FAQ

What specific items are covered under the 'Departure of Directors or Certain Officers' section?

The filing indicates that it covers the departure of directors or certain officers, though specific names or details of departures are not provided in this summary.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is May 21, 2025.

What is Zoetis Inc.'s state of incorporation?

Zoetis Inc. is incorporated in Delaware.

What is the company's Standard Industrial Classification (SIC) code?

The SIC code for Zoetis Inc. is 2834, which corresponds to Pharmaceutical Preparations.

What are the key items reported under Item Information in this 8-K?

The key items reported are: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Submission of Matters to a Vote of Security Holders; and Financial Statements and Exhibits.

From the Filing

0001555280-25-000213.txt : 20250522 0001555280-25-000213.hdr.sgml : 20250522 20250522162650 ACCESSION NUMBER: 0001555280-25-000213 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250521 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250522 DATE AS OF CHANGE: 20250522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zoetis Inc. CENTRAL INDEX KEY: 0001555280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 460696167 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35797 FILM NUMBER: 25977518 BUSINESS ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-822-7000 MAIL ADDRESS: STREET 1: 10 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 8-K 1 zts-20250521.htm 8-K zts-20250521 0001555280 false 0001555280 2025-05-21 2025-05-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 21, 2025 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 001-35797 46-0696167 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification No.) 10 Sylvan Way, Parsippany, New Jersey 07054 (Address of principal executive offices) (Zip Code) ( 973 ) 822-7000 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐     Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share ZTS New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                      Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective May 21, 2025, Mr. Robert Scully retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2025 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy. Effective

View on Read The Filing